In this regard, the significant direct correlation between PCSK9 and both disease activity and immune–inflammatory parameters, independently of lipid profile, in SLE and RA patients may support a possible relationship between this molecule and the dysregulation of immune–inflammatory pathways [25,26,27,28]. This evidence concerns the gene PCSK9 and systemic lupus erythematosus.